• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
OTC Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide - Product Image

OTC Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide

  • ID: 2134157
  • August 2013
  • Region: Brazil, China, India, Russia
  • 105 pages
  • MarketLine

Introduction

The BRIC OTC Pharmaceuticals industry guide provides top-line qualitative and quantitative summary information including: market share, market size (value 2008-12, and forecast to 2017). The guide also contains descriptions of the leading companies including key financial metrics and analysis of competitive pressures within the market.

Features and benefits

- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the OTC pharmaceuticals market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the BRIC OTC pharmaceuticals market
- Leading company profiles reveal details of key OTC pharmaceuticals players' BRIC operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the BRIC OTC pharmaceuticals market with five year forecasts
- Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country

Highlights

Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the OTC READ MORE >

Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
BRIC OTC Pharmaceuticals
Industry Outlook
OTC Pharmaceuticals in Brazil
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
OTC Pharmaceuticals in China
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
OTC Pharmaceuticals in India
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
OTC Pharmaceuticals in Russia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology

LIST OF TABLES
Table 1: BRIC OTC pharmaceuticals industry, revenue($m), 2008-17
Table 2: BRIC OTC pharmaceuticals industry, revenue($m), 2008-12
Table 3: BRIC OTC pharmaceuticals industry, revenue($m), 2012-17
Table 4: Brazil OTC pharmaceuticals market value: $ million, 2008–12
Table 5: Brazil OTC pharmaceuticals market category segmentation: $ million, 2012
Table 6: Brazil OTC pharmaceuticals market geography segmentation: $ million, 2012
Table 7: Brazil OTC pharmaceuticals market share: % share, by value, 2012
Table 8: Brazil OTC pharmaceuticals market distribution: % share, by value, 2012
Table 9: Brazil OTC pharmaceuticals market value forecast: $ million, 2012–17
Table 10: Brazil size of population (million), 2008–12
Table 11: Brazil gdp (constant 2000 prices, $ billion), 2008–12
Table 12: Brazil gdp (current prices, $ billion), 2008–12
Table 13: Brazil inflation, 2008–12
Table 14: Brazil consumer price index (absolute), 2008–12
Table 15: Brazil exchange rate, 2008–12
Table 16: China OTC pharmaceuticals market value: $ million, 2008–12
Table 17: China OTC pharmaceuticals market category segmentation: $ million, 2012
Table 18: China OTC pharmaceuticals market geography segmentation: $ million, 2012
Table 19: China OTC pharmaceuticals market share: % share, by value, 2012
Table 20: China OTC pharmaceuticals market distribution: % share, by value, 2012
Table 21: China OTC pharmaceuticals market value forecast: $ million, 2012–17
Table 22: China size of population (million), 2008–12
Table 23: China gdp (constant 2000 prices, $ billion), 2008–12
Table 24: China gdp (current prices, $ billion), 2008–12
Table 25: China inflation, 2008–12
Table 26: China consumer price index (absolute), 2008–12
Table 27: China exchange rate, 2008–12
Table 28: India OTC pharmaceuticals market value: $ million, 2008–12
Table 29: India OTC pharmaceuticals market category segmentation: $ million, 2012
Table 30: India OTC pharmaceuticals market geography segmentation: $ million, 2012
Table 31: India OTC pharmaceuticals market share: % share, by value, 2012
Table 32: India OTC pharmaceuticals market distribution: % share, by value, 2012
Table 33: India OTC pharmaceuticals market value forecast: $ million, 2012–17
Table 34: India size of population (million), 2008–12
Table 35: India gdp (constant 2000 prices, $ billion), 2008–12
Table 36: India gdp (current prices, $ billion), 2008–12
Table 37: India inflation, 2008–12
Table 38: India consumer price index (absolute), 2008–12
Table 39: India exchange rate, 2008–12
Table 40: Russia OTC pharmaceuticals market value: $ million, 2008–12
Table 41: Russia OTC pharmaceuticals market category segmentation: $ million, 2012
Table 42: Russia OTC pharmaceuticals market geography segmentation: $ million, 2012
Table 43: Russia OTC pharmaceuticals market share: % share, by value, 2012
Table 44: Russia OTC pharmaceuticals market distribution: % share, by value, 2012
Table 45: Russia OTC pharmaceuticals market value forecast: $ million, 2012–17
Table 46: Russia size of population (million), 2008–12
Table 47: Russia gdp (constant 2000 prices, $ billion), 2008–12
Table 48: Russia gdp (current prices, $ billion), 2008–12
Table 49: Russia inflation, 2008–12
Table 50: Russia consumer price index (absolute), 2008–12
Table 51: Russia exchange rate, 2008–12
Table 52: Abbott Laboratories: key facts
Table 53: Abbott Laboratories: key financials ($)
Table 54: Abbott Laboratories: key financial ratios
Table 55: GlaxoSmithKline Plc: key facts
Table 56: GlaxoSmithKline Plc: key financials ($)
Table 57: GlaxoSmithKline Plc: key financials (£)
Table 58: GlaxoSmithKline Plc: key financial ratios
Table 59: Johnson & Johnson: key facts
Table 60: Johnson & Johnson: key financials ($)
Table 61: Johnson & Johnson: key financial ratios
Table 62: Sanofi: key facts
Table 63: Sanofi: key financials ($)
Table 64: Sanofi: key financials (€)
Table 65: Sanofi: key financial ratios
Table 66: Huangshan Tianmu Pharmaceutical Co., Ltd.: key facts
Table 67: Nin Jiom Medicines Manufactory: key facts
Table 68: Cipla Limited : key facts
Table 69: Cipla Limited : key financials ($)
Table 70: Cipla Limited : key financials (Rs.)
Table 71: Cipla Limited : key financial ratios
Table 72: Dabur India Limited : key facts
Table 73: Dabur India Limited : key financials ($)
Table 74: Dabur India Limited : key financials (Rs.)
Table 75: Dabur India Limited : key financial ratios
Table 76: JSC ELFA: key facts
Table 77: Menarini Group: key facts
Table 78: Pharmstandard OJSC: key facts
Table 79: Pharmstandard OJSC: key financials ($)
Table 80: Pharmstandard OJSC: key financials (RUB)
Table 81: Pharmstandard OJSC: key financial ratios

LIST OF FIGURES
Figure 1: BRIC OTC pharmaceuticals industry, revenue($m), 2008-17
Figure 2: BRIC OTC pharmaceuticals industry, revenue($m), 2008-12
Figure 3: BRIC OTC pharmaceuticals industry, revenue($m), 2012-17
Figure 4: Brazil OTC pharmaceuticals market value: $ million, 2008–12
Figure 5: Brazil OTC pharmaceuticals market category segmentation: % share, by value, 2012
Figure 6: Brazil OTC pharmaceuticals market geography segmentation: % share, by value, 2012
Figure 7: Brazil OTC pharmaceuticals market share: % share, by value, 2012
Figure 8: Brazil OTC pharmaceuticals market distribution: % share, by value, 2012
Figure 9: Brazil OTC pharmaceuticals market value forecast: $ million, 2012–17
Figure 10: Forces driving competition in the OTC pharmaceuticals market in Brazil, 2012
Figure 11: Drivers of buyer power in the OTC pharmaceuticals market in Brazil, 2012
Figure 12: Drivers of supplier power in the OTC pharmaceuticals market in Brazil, 2012
Figure 13: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Brazil, 2012
Figure 14: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Brazil, 2012
Figure 15: Drivers of degree of rivalry in the OTC pharmaceuticals market in Brazil, 2012
Figure 16: China OTC pharmaceuticals market value: $ million, 2008–12
Figure 17: China OTC pharmaceuticals market category segmentation: % share, by value, 2012
Figure 18: China OTC pharmaceuticals market geography segmentation: % share, by value, 2012
Figure 19: China OTC pharmaceuticals market share: % share, by value, 2012
Figure 20: China OTC pharmaceuticals market distribution: % share, by value, 2012
Figure 21: China OTC pharmaceuticals market value forecast: $ million, 2012–17
Figure 22: Forces driving competition in the OTC pharmaceuticals market in China, 2012
Figure 23: Drivers of buyer power in the OTC pharmaceuticals market in China, 2012
Figure 24: Drivers of supplier power in the OTC pharmaceuticals market in China, 2012
Figure 25: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in China, 2012
Figure 26: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in China, 2012
Figure 27: Drivers of degree of rivalry in the OTC pharmaceuticals market in China, 2012
Figure 28: India OTC pharmaceuticals market value: $ million, 2008–12
Figure 29: India OTC pharmaceuticals market category segmentation: % share, by value, 2012
Figure 30: India OTC pharmaceuticals market geography segmentation: % share, by value, 2012
Figure 31: India OTC pharmaceuticals market share: % share, by value, 2012
Figure 32: India OTC pharmaceuticals market distribution: % share, by value, 2012
Figure 33: India OTC pharmaceuticals market value forecast: $ million, 2012–17
Figure 34: Forces driving competition in the OTC pharmaceuticals market in India, 2012
Figure 35: Drivers of buyer power in the OTC pharmaceuticals market in India, 2012
Figure 36: Drivers of supplier power in the OTC pharmaceuticals market in India, 2012
Figure 37: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in India, 2012
Figure 38: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in India, 2012
Figure 39: Drivers of degree of rivalry in the OTC pharmaceuticals market in India, 2012
Figure 40: Russia OTC pharmaceuticals market value: $ million, 2008–12
Figure 41: Russia OTC pharmaceuticals market category segmentation: % share, by value, 2012
Figure 42: Russia OTC pharmaceuticals market geography segmentation: % share, by value, 2012
Figure 43: Russia OTC pharmaceuticals market share: % share, by value, 2012
Figure 44: Russia OTC pharmaceuticals market distribution: % share, by value, 2012
Figure 45: Russia OTC pharmaceuticals market value forecast: $ million, 2012–17
Figure 46: Forces driving competition in the OTC pharmaceuticals market in Russia, 2012
Figure 47: Drivers of buyer power in the OTC pharmaceuticals market in Russia, 2012
Figure 48: Drivers of supplier power in the OTC pharmaceuticals market in Russia, 2012
Figure 49: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Russia, 2012
Figure 50: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Russia, 2012
Figure 51: Drivers of degree of rivalry in the OTC pharmaceuticals market in Russia, 2012
Figure 52: Abbott Laboratories: revenues & profitability
Figure 53: Abbott Laboratories: assets & liabilities
Figure 54: GlaxoSmithKline Plc: revenues & profitability
Figure 55: GlaxoSmithKline Plc: assets & liabilities
Figure 56: Johnson & Johnson: revenues & profitability
Figure 57: Johnson & Johnson: assets & liabilities
Figure 58: Sanofi: revenues & profitability
Figure 59: Sanofi: assets & liabilities
Figure 60: Cipla Limited : revenues & profitability
Figure 61: Cipla Limited : assets & liabilities
Figure 62: Dabur India Limited : revenues & profitability
Figure 63: Dabur India Limited : assets & liabilities
Figure 64: Pharmstandard OJSC: revenues & profitability
Figure 65: Pharmstandard OJSC: assets & liabilities

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos